EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary
November 15, 2021
Earnings Call Speaker Segments
Nicola Fiore
executiveGood afternoon, everyone, and welcome to the conference call covering El.En.'s financial results for the third quarter and the nine months. This call is being recorded, so there will be a chance to ask questions at the end of it. Joining me are Andrea Cangiani, El.En.'s Managing Director, and Enrico Romagnoli, El.En.'s Chief Financial Officer and Investor Relations. Before we start, please be aware that management will make a remark on this conference call regarding future expectations, plans and prospects, and forward-looking statements. Some statements on this call — including those addressing the company's beliefs, plans, objectives, estimates, or expectations of possible future results or events — are forward-looking statements. Forward-looking statements carry known or unknown risks, including general economic and business conditions, and conditions in the industry the company operates, and they may be affected if the assumption proves inaccurate. As a result, no forward-looking statement can be guaranteed, and actual future results, performance, or achievements may differ materially from those expressed or implied by such forward-looking statements. The company assumes no obligation regarding the contents, nor to update the forward-looking statement to reflect events or circumstances that may arise after the date hereof. At this time, I want to turn the call over to Andrea Cangiani.
Nicola Fiore
executiveAndrea, you have the floor.
Andrea Cangiani
executiveThank you, Nicola. Good morning and good afternoon, everyone. We appreciate your joining us for this earnings call following the release of the Q3 2021 financials. The third quarter of 2021 represented yet another exceptionally strong quarter, characterized by rapid growth and high profitability. We remain in a very positive phase, and our results are solid and do not appear to be softening. Revenue for the quarter came in at EUR 131 million, an increase of 24.4% compared with the same quarter of 2020 — which, incidentally, was a record third quarter — and bringing consolidated turnover after nine months to EUR 405 million, up 51% on 2020. EBIT for the quarter stood at EUR 13.17 million, up 55% on the corresponding quarter of 2020, and for the year we are at EUR 44.6 million, which is already well above any other previous full year. When comparing our financial results with those of the past, it is important to keep in mind that the first six months of 2020 do not constitute a very sound benchmark for our current results, since during that period we were heavily affected by pandemic restrictions — initially forced to halt production for months in Wuhan and in Guangzhou, and then in Italy for the industrial sector, and subsequently facing an unprecedented shift in demand on the medical market.
Andrea Cangiani
executiveDuring Q3 2020, the economy began to stabilize following the first shock from the pandemic, and our performance turned strong once more. That's why we're finishing up — and Enrico will wrap up my presentation with the financial specifics. We'll walk you through numbers of this kind. We're rounding out the financial presentation by comparing against the 2019 results using average compound annual growth, so you get a sense of what we've accomplished — which shouldn't be exaggerated the way the +50% growth in 2020 might imply, but should be valued within the continuity across the two years. Compared with the first nine months of 2019, average revenue growth came in near 20%, while for EBIT it was near 30%. Again, I take pleasure in what this organization has managed to accomplish and in my confidence in its strengths. Even at the risk of sounding repetitive, I must tell you just how deep our know-how and skills run in the core technologies required to design our products, and how broadly they span technical and application expertise that's useful across multiple technologies and application markets — letting us lead in particular segments and making us formidable competitors to the market leaders in several others.
Andrea Cangiani
executiveHonestly, I don't believe anyone else in our field matches us when it comes to the depth and breadth of expertise we have. Among the markets where we're performing strongly, aesthetics led the way this quarter. Our hair removal systems are seeing unprecedented success — both the Alexandrite units from DEKA and Quanta System, and the diode systems made by Asclepion, which Esthelogue distributes globally and in Italy for the professional aesthetic market. I'm referring to the non-medical market. Our body shaping devices also did extremely well, building on Coolwaves, which returned to record sales volume after 2020, when the body season — that's the spring — was miserably lost because of the pandemic. We're now set to begin U.S. distribution with a dedicated distribution partner for Onda. We already sell another product in the U.S., the Physiq, through our aesthetic distributor for DEKA and Quanta, which is called Cartessa. Physiq is a body shaping device built on superluminescent LED technology — a technology that cannot deliver the triple claim of microwaves: fat removal, cellulite and tightening. Of those, it's suitable for fat removal only, but it's an extremely effective device, easy to use, and it enables unmanned treatments, and that's why it's very successful right now.
Andrea Cangiani
executivePhysiotherapy—that small yet highly profitable piece—is growing again and adding to the group's overall results. Within the service segment, output of optical fibers for urology, which drives most of our consumable sales volume, came in extremely strong this quarter. During a substantial stretch of Q1 of 2021, we ran into serious production issues. Volumes are now back to standard levels, and over the next few months we expect to be able to push capacity even higher so we can satisfy the greater demand. Optical fibers for urology lead us into the urology segment, and in this Q3 it is giving us signals of material recovery, although it remains under the 2019 record. Everyone, if you could switch off your microphone, please—I think that would help the presentation. Thank you. The introduction of Quanta's
Nicola Fiore
executiveAppreciate it.
Andrea Cangiani
executiveA fiber laser-based system marked our entry in the last months into this technological approach to lithotripsy, one of the most significant segments for us in urology. This technology is quite new for us, since we gained our market position in urology and in lithotripsy based on solid-state lasers, and we needed currently to accommodate our production and our offer to the current market trend, which is very appreciative of certain advantages of the fiber introduced and promoted by a certain competitor of us. Research and development has in the pipeline new solid-state technology devices, which are expected to overcome the limitation, both of the current solid-state devices and of the fiber laser systems. The overall financial results of our industrial markets were excellent once again. The minor segments of marking and CO2 laser sources are doing well again. The main segment of laser cutting had another very strong quarter, beating 2020 with revenue once again well over the initial projections. Very well therefore. But the win on the forecast is not as wide as it was in the first half. The Italian facility serving mainly the Italian and European markets is still overwhelmed by its backlog, and its production has to further accelerate in order to meet the volumes that we count on for this final quarter, Q4 2021.
Andrea Cangiani
executiveAs summer arrived, the Chinese market has instead moved into a period of slower growth. A significant deceleration in growth, essentially driven by the broader cooling of China's economy. The highly competitive laser cutting market is feeling this as well. We performed well and expect to keep performing well, thanks to the particular edge that laser cutting technology brings to the market, both broadly and in our own offering, which rests on very high power laser systems and application. Those applications include the ones we serve today, and we are enhancing their productivity. We are also developing new applications by moving into new niches, drawing on the fresh capabilities that higher power makes possible. When I say high power, I mean that the average power of the systems we sell now exceeds 10 kilowatts. To be clear, 20 kilowatts have been standard for 1 year, 30 kilowatts have been standard since this year, and 40-kilowatt laser systems are set to become a new standard in 2022. To give one example of a potential application, I was discussing exactly this morning with our Chinese management. We are moving into the construction world, where our 30 kW and 40 kW laser sources hold a clear advantage over the plasma cutters that this industry currently uses.
Andrea Cangiani
executiveSo for that reason, we keep relying on the laser market's particular dynamics and on the competitive edge that is specific to us, though we do have to accept the general deceleration of China's economy. One more thing worth noting: at this point of a very robust close-out in China, where any visitor arriving from abroad faces lengthy quarantine and leaving the country is heavily restricted, that entire set of conditions works against us in the export business, which had been growing its volumes toward neighboring countries. A few remarks on our cash position — just a general observation: it remains very strong. It went up over the year, though it dipped slightly in Q3. We moved EUR 3 million into our financial investment, which is actually available for immediate sale but must be recorded outside the net financial position. The biggest effect came from the substantial rise in our inventory level. Such an increase has two principal causes. First, as a seasonally slow quarter ends, we are getting the materials ready for our strongest quarter, the fourth quarter. Second, strains in the supply chain have grown and rendered erratic the lead times several vendors give. So we chose to raise the purchase order volume and the amount of safety stock held in-house, given the volume growth anticipated for the end of the year and for 2022 as well.
Andrea Cangiani
executiveThat final point about supply chain problems isn't a small thing. In fact, it's the toughest challenge we had to deal with during these months. From the outside, you see the fairly polished surface of our strong results. But behind the curtain, an enormous amount of effort has gone in, and continues to go in, so we can hit the target sales volume. The count of manufactured units — which is what sales volume reflects — would have been significantly higher if not for these kinds of difficulties over the last months. The work we've had to carry out because of the disruption that supply chains have caused in our manufacturing process is highly unusual. Getting materials and component inputs to our lines has been a genuine nightmare. Suppliers are unable to honor confirmed delivery deadlines for a number of materials — and not just the microchips that everyone mentions, but also more ordinary integrated circuits, capacitors, plastic parts, metal parts, copper parts, including, for instance, the heat exchanger, a critical component in a laser system. Missing parts pushed us to rework production schedules, and also to engineer around certain long-term shortfalls so that the production flow wouldn't be interrupted. At a stage when we're being asked to speed up our production phase sharply to satisfy record demand across several market segments, we must operate with this handbrake engaged, and only a tremendous effort by our manufacturing and technical departments enabled us to get past these obstacles, to the degree that we managed it.
Andrea Cangiani
executiveLike we said in both the press release and the report, conditions remain critical and are to some degree running counter to the prospect of much faster additional expansion that our backlog is pointing to. We're putting in effort to get past these hurdles and to keep posting substantial growth results over the months ahead. That wraps up my opening remarks. Enrico, over to you.
Enrico Romagnoli
executiveThanks, Andrea. As is customary, I'll offer some remarks on the latest financials. During the first nine months of 2021, carrying on from where 2020 ended, the group's growth trajectory persisted following the pause caused by COVID's effects. Across those nine months, turnover rose 51% and came to EUR 405 million — about the same figure as the turnover generated over the entirety of 2020. Since comparing against 2020 isn't especially meaningful given the COVID restrictions and the constraints that hit us hard mainly in the first six months of last year, we also set the 2021 results against the 2019 financial results. We observe aggregate average growth of close to 20%. Gross margins came in above EUR 150 million, up 59% versus last year and more than 60% versus 2019, reflecting the substantial rise in turnover. Looking at margin on sales, there's a decisive recovery, helped by margin improvement in both main sectors. Against 2019, the comparison revealed a decrease stemming from a different sales mix between medical and industrial, since industrial structurally carries a lower margin than medical. Operating costs totaled EUR 34 million, higher than in 2020, yet their impact on turnover fell, going from 8.9% on September 2020 to 8.4% on September 2021, and the reduction relative to 2019 is even more pronounced.
Enrico Romagnoli
executiveWithin this cost total, we gain from reduced commercial spending, but savings on international travel and trade fair and congress activities—especially in the medical sector—make up a substantial expense. We went to some international conferences in September, yet a long time will still be needed before travel, congress, and trade fair events return to pre-COVID intensity. Staff costs of EUR 60.5 million are higher than the EUR 44.7 million of September 2020. Their effect on turnover is lower, falling from 16.7% to 14.9% from September 2021, and below 2019 as well. At September 2021, we employed more than 1,800 staff. Because turnover rose and fixed costs were absorbed better, EBITDA came to 55.7 million euros, over twice 2020, and its impact on sales climbed from 13.7% versus the 9.6% of last year. Amortization and other accruals rose markedly, from EUR 7.6 million in 2020 to EUR 11 million in 2021, while their incidence on turnover is essentially unchanged. The largest increase concerned warranty provision, reflecting higher sales volume and some lengthening of the warranty period. In 2021, total fixed cost as operating cost, of course, and depreciation rose by almost 30%, but the impact on sales fell from 28% to 26%.
Enrico Romagnoli
executiveBecause gross margin improved and fixed-cost impact was reduced, the operating result showed a positive balance of EUR 44 million — a strong rise from EUR 18 million in 2020 — and its incidence on turnover climbed to 11% from 6.8% in the same period last year and also versus 2019, when it stood at 9.3%. The tax result came to EUR 45 million, helped by a positive forex effect driven mainly by the US dollar, which strengthened against the euro during the period. Net financial position rose by roughly EUR 10 million in the period, from 64.2 million last December to 75 million in September 2021. As required by ESMA and adopted by CONSOB for the financials as of June 2021, net financial position must include long-term payables, even where these are not financial liabilities. The largest long-term debt previously excluded from net financial position is owed to the former minority shareholders of Penta, totaling CNY 40 million — approximately EUR 5 million — payable under an earn-out clause in the 2020 sales contract should Penta Wenzhou complete an IPO within five years of the purchase date.
Enrico Romagnoli
executiveLooking at the income statement for the third quarter, you'll notice that even during the summer months, our results stayed outstanding in spite of seasonality being less favorable — turnover came in at EUR 130 million, which is 24% higher than 2020, and the operating result reached EUR 13.7 million, an increase of 55%. On cash flow, we produced cash from operating activities, though there was a cash absorption caused by working capital going up, which is physiological during this stage of fast growth. Cash flow was positive for other current payables and receivables, driven mainly by higher advances received from customers — a practice that carries substantial volume in China. Across the first nine months, the group saw a cash absorption from a EUR 19 million investment, of which CapEx account for roughly EUR 16 million and EUR 3 million is a midterm cash investment that Andrea already mentioned and that isn't included in net financial position. If you exclude that investment, net financial position went down by EUR 1 million during the quarter. The biggest investment over the nine months was Cutlite Penta's new building in Prato, at EUR 5 million, acquired through a leasing in January. El.En.
Enrico Romagnoli
executiveThe subsidiary also went back to paying a dividend of EUR 9 million, and the capital increase the company raised through employees exercising their assigned stock options — amounting to EUR 4 million — helped improve the net financial position as well. Let me remind you that the net financial position excludes EUR 18 million of investment in insurance policy. Given their character as mid- to long-term investments, these are classified among non-current financial assets, which means they are not counted in the net financial position. Turning to the revenue breakdown by business, which this chart also presents, we compare 2021 with 2020 and with 2019 too. As we can see, the aggregate growth rate in medical comes to 14%. The largest gain, we can see, came in the aesthetic sector, with a very significant jump, driven by solid growth, particularly in hair removal and body contouring applications, thanks to an offer of innovative systems and to a positive market phase. In surgery, recovery got underway more slowly than in other segments and is measured as well against a record result in 2019. The objective difficulties tied to focusing hospital activities on COVID have been compounded in recent months by the growing adoption of the urological system built on fiber optic source technology.
Enrico Romagnoli
executivePhysiotherapy has bounced back strongly, with ASA returning to the growth trajectory it saw in prior years. After-sales service turnover was solid as well. That figure covers revenue tied to laser maintenance along with spare parts and consumable sales. Growth trends in this segment remain favorable. That's also thanks to getting past the production issues — first technical, then production capacity — that held back optical fiber sales for urology through the opening months of 2021. The industrial sector shows a CAGR of 29% above the medical sector, with the cutting sector turning in an exceptional performance and running at very high rates, +35%. These are the production and sales volumes that production capacity was built for through significant investment, which is now being used increasingly and is helping profitability too. Laser sources also trended very positively, recovering quickly from last year, while the marking sector has returned to its pre-COVID turnover level. Growth is meaningful across every geographic area where the group operates. Europe stands out in the medical sector, whereas industrial growth is nearly uniform, with Europe slightly behind the rest of the world.
Enrico Romagnoli
executiveAndrea, go ahead and give us the guidance. Andrea?
Andrea Cangiani
executiveSorry about that — I had been on mute. As for the guidance, we're reaffirming the outlook we provided in September, following the six-month financials. Growth will continue, and on revenue we will surpass the EUR 550 million threshold, while in the second half we will likewise top the EBIT figure we posted in the first half. That wraps up the prepared presentation, and we're ready now to take your questions.
Operator
operatorNicola, please continue. All right. François Rabia has sent in one question. Please go ahead, François.
François Rabia
analystHello, and good afternoon to everyone; I appreciate you taking my question. I have one quick item regarding your FY 2021 guidance. If we look at the low end of your revenue outlook, it suggests single-digit growth for the group during the fourth quarter, whereas a number of your peers in medical lasers are indicating sales growth above 20% for that same fourth quarter. Could you comment on this, and also share a little more detail regarding the growth trends you anticipate in the fourth quarter for each division? And following that, we observed an acceleration in fixed operating costs during the third quarter. Is that solely attributable to traveling costs returning, or is there anything additional we should anticipate, which would also recur over the coming quarters? Lastly, if you could provide an initial indication of what you expect for 2022, some broad expectations would be helpful. Are there any new products that we ought to know about? Is the surgical recovery witnessed in the third quarter expected to accelerate further over the coming months? Thank you so much.
Speaker
unknownYou know, your solution and your software, and the way Tier One evaluates it — sorry, the way OEM evaluates it, or how that partnership with Tier One has been working.
Enrico Romagnoli
executiveWould you mind turning off your mic? Thanks.
Andrea Cangiani
executiveFirst question. Yes. You're correct. I mean, if we were to hit EUR 551 million, that would represent a very strong growth rate for the fourth quarter. The comparison base right now is a very good quarter, since Q4 2020 was a very good quarter. I should tell you that we anticipate strong growth in medical. We anticipate good growth in industrial, even though, as I was saying, a large piece of our industrial world is China, where growth is decelerating. We're very positive, especially in aesthetics. For sure, if we are going to overcome, as we have done in these last months, the production issues that are really creating serious trouble in our day-to-day work, we should continue a very solid growth for medical. Regarding the costs, there has been a slight increase across all the costs, and the slight increase in the sales and marketing costs will progressively continue over time. The most significant increase, if you look at the various single lines, was not a sales and marketing expense, but was an expense much wider than in the past for R&D in China, where we had a record expense in this quarter, as much as we are having a record effort in order to continually improve our product line.
Andrea Cangiani
executiveLike I said during my presentation, in China — a market that's extremely competitive — we have to make our product stand out strongly versus the competition so we can keep up our growth trajectory, and we're still counting on that path for the upcoming quarter and the coming year. Because of that, expenses were especially elevated this quarter. Broadly speaking, I don't see costs coming down over the next few months. What I'd look for is higher revenues so we can better absorb rising costs. This quarter was negative on the industrial side — not particularly in China — but it wasn't a good quarter for manufacturing at the Italian plant, which operated far under its present capacity, since we were in a sense adjusting everything to be ready for the final 2021 rush; that rush also anticipates, in cutting systems, Q4 revenue materially bigger than what we booked in Q3. As for 2022, right now we still maintain a very strong outlook for all the work connected to medical laser applications. In this case, in this business, our backlog is growing, and the length of certain orders we're taking in is growing too. Given that our delivery times aren't as fast as they used to be, we have more customers planning production across 2022, and I'd say, for the moment, that planning looks very, very good.
Andrea Cangiani
executiveOn the industrial side, planning remains near-term — or at least shorter in horizon than what we see in medical under these conditions. Deliveries for 2022 are already being booked by us, so we expect our activity to rise further in 2022.
Operator
operatorAndrea, there’s a further question coming in from Andrea Bonfà. Please proceed, Andrea. Thanks.
Andrea Bonfà
analystHello, and good afternoon, everyone. I’m hoping you’re able to hear me. What I’d like to ask about concerns the gross margin—specifically, given what you’ve described as a supply chain constraint, and also a mix that is accelerating versus medical, whether you could go into detail about what sort of expectation we should have for the gross margin. Can you get back to the peak level, or is industrial now structurally lower, though perhaps medical can offset that? I’m just looking for some sense of where you can go on the gross margin level, because the improvement in the third quarter was quite nice and quite sharp. Naturally, you’ve got higher cost, but some of those have been explained during your call. It appears to me that with acceleration in medical there is additional room for the gross margin to improve. I’d like to hear your thoughts on it. Thank you very much.
Andrea Cangiani
executiveCorrect. That's accurate. Our Q3 performance was strong on margin, and that came not just from medical carrying more relative weight than industrial — we actually did well in both segments. Margin went up in medical and in industrial alike. On the industrial side, I don't think we're in a spot where margins are going to rise, partly because the lower-margin cutting business will carry an even more overwhelming weight in the fourth quarter. Q3 saw softer sales in cutting, but Q4 will bring stronger cutting sales, and those will overwhelm the smaller industrial sectors that carry a high margin. I don't foresee margin improvement, or a continuation of the margin improvement, in the industrial sector. In medical, I do see room to keep raising margins thanks to the dollar exchange rate — after hurting our U.S. sales throughout the whole year, it's now giving them a lift. I also note we had fewer sales in Japan in aesthetics, reflecting low-margin local sales. Normally we book EUR a few million per quarter of sales that our local subsidiary handles in pure distribution, with just a fairly small gross margin, but which keeps us present on the market.
Andrea Cangiani
executiveWe're all for that. As that portion of sales declines, the segment's total gross margin goes up. There's one uncertainty here. It's a factor we can't precisely model. Without a doubt, the surge in costs will begin affecting our production expenses over the coming months, since we've been buying materials at progressively higher prices across several material types. A portion of these cost rises gets offset at the manufacturing level through purchasing volumes and overall volumes for production overhead. As volumes grow, we ought to be able to counteract that effect. Naturally, that remains an open question as we move ahead. To put it briefly, my view is that we should manage to keep margins higher in Medical, yet we should not be in a position to lift margins further in Industrial, while in Q4 we should see a positive impact from greater volume compared with Q3.
Andrea Bonfà
analystAndrea, thanks so much. If I could just ask — given that China and Europe are dealing with the same macroeconomic situation, is it fair to say that a slowdown in Chinese industrial activity might be offset by, say, faster growth in Europe or Italy?
Andrea Cangiani
executiveSure, if we’re talking percentages. Right now, our business in Italy and Europe is roughly half of what we do in China. So when you look at the actual numbers in the end, I don’t think they’ll line up. That said, I’m confident that by the close of the quarter, we’ll see solid results in the cutting business.
Andrea Bonfà
analystAll right, thanks a lot, Andrea.
Andrea Cangiani
executiveThat's appreciated. Thanks, Andrea.
Operator
operatorHi there, Manon?
Manon Culaud
analystHi.
Nicola Fiore
executiveManon Culaud is on the line for us. Please go ahead, Manon.
Manon Culaud
analystHi, thanks for taking my question. I just have one, if I may. Could you give us a little more detail on the slowdown in China? Can you tell us the kind of growth you saw in Q2 and Q3, and maybe what you expect for Q4 and for 2022? Thanks.
Andrea Cangiani
executiveWhat kind of what did we have? Pardon me. I wasn't able to hear.
Manon Culaud
analystI apologize — regarding China's growth, since you mentioned relative deceleration, could you give us a sense of what that figure was, what type of slowdown occurred between Q2 and Q3, and what we should anticipate for Q4, for 2021, and for 2022?
Andrea Cangiani
executiveGive me a moment. The figures aren't in front of me. I need to pull up a file. One second. I'll get to it quickly. For Q3 in China, comparing this year's Q3 with Q3 of last year, growth came in at roughly 3%, whereas Q2 versus Q2 showed 53% growth, and Q1 versus Q1 was 223.3%. Naturally, you have to keep in mind what took place in China a year ago. Comparing against Q1 makes no sense, since we weren't operating in China during Q1 2020. In Q2 we began operating, yet conditions remained very complicated. Q3 2020 was a record quarter — the first quarter when we resumed selling, and we got back on track. So this Q3 faces the hardest comparison, because China revenues in Q3 were — well, we actually did even better in Q4, but they were by far a record for the quarter. As for Q4, what we're attempting, I mean, is that we hope to match last year's China revenue. Under these circumstances, that's something that could happen, but it isn't certain we'll be able to beat the Q4 2020 China revenue by a wide margin. At the same time, we're in the position, as Andrea Bonfà's question suggests, of being fairly confident that we'll surpass Cutlite Penta's revenues — that's the Italian division of the cutting division — in Q4 by a notable amount.
Andrea Cangiani
executiveUnderstood, thank you very much. As for 2022, it remains too soon to say what 2022 will bring, and how the order books we hold today will carry through into 2022. Naturally, how China performs will hinge to a great extent on the orders we manage to book during these coming weeks before the year ends and in the opening weeks of 2022. As I mentioned to you, orders softened over December. Activity now looks better than it did in the summer. We continue to observe that China's overall economy has certain broad issues. On the other hand, our confidence in our products is extremely high, and we are extremely confident that our specialties — I mean the high power laser sources for very specific application — could let us continue on the rapid growth path we are looking forward to obtaining also in 2022.
Operator
operatorAndrea, there's another question coming in from Marco Riva. Marco, please go ahead.
Marco Riva
analystHey there, good afternoon, everyone. I’ve got just one question. Before you respond, regarding what was asked earlier about the spare capacity you already have, again, in Italy — I’d like to ask whether that same situation applies everywhere, and whether you could give us some color on your CapEx plan going forward. Thanks.
Andrea Cangiani
executiveRight now, we likely have some unused capacity in China, since CapEx proceeded as planned there, and compared with last year we have two additional factories running, one in Linyi and one in Wenzhou. Our capacity in the medical business needs to be improved. This isn't expected to need huge investments, but it will call for investments to set up the second building of Quanta System, which was bought a couple of years ago and whose surface has not been used yet. Some investment will be needed for it to be used. Also here in Florence, we will need to refurbish some existing buildings so we can accommodate a further production increase. We are planning a very strong production increase in both Florence and Milan for 2022. We could be expanding our production capacity in China again in the city of Wuhan, which was our original production site, where we currently operate on a leased facility. It looks like the Wuhan development area is offering us a large piece of land so we can build our factory. If everything works well, we could have the opportunity to expand our production footprint in Wuhan only.
Andrea Cangiani
executiveIn Wuhan as well, we did the same as in the other cities. Broadly speaking, I expect capital expenditure for 2022 to come in below 2021, since we shouldn’t be making big investments of the kind we made — the EUR 5 million in Cutlite Penta and the close to EUR 2.5 million each in Wuhan and Wenzhou, which were spent or will be spent by the end of the year. Apart from other investments in general toolings or in other plants, I think that this sort of investment — real estate investment in 2022, let’s say — should be roughly half of what it was in 2021.
Marco Riva
analystMuch appreciated.
Operator
operatorHi, Andrea. No further questions have come in for us. Still, I’d like to check whether any other question exists. If nothing else has come in, we’ll bring this conference to a close. Should you have additional questions you want to look into, please feel free to reach out to Enrico Romagnoli. He’ll be glad to respond to your question. Thanks for joining this conference, and we hope to have all of you with us next time. Good afternoon, everyone.
Andrea Cangiani
executiveThanks a lot, everyone.
Operator
operatorThanks.
Marco Riva
analystThanks.
Operator
operatorAppreciate it. Goodbye.
Andrea Cangiani
executiveThat’s all from me.
Operator
operatorBye. <<foreign_lang>>.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.